You are endorsing Multistem with a tattoo telling us that it has passed your inspection.
It is ready for release from the machine shop.
I hope you are right!
screwed, blued and tattooed
Unlike the imaginative explanations given, the definition goes way back to early machinists. After inspecting a finished manufactured or repaired part, the toolmaker/machinist would
1 tighten all parts and screws (Screwed)
2 Use bluing a blue paint like stain that stuck easily to metal (blued) and
3 Put his inspectors mark through the blue paint with a sharp scriber (tattooed)
The part has passed inspection, it's been screwed, blued and tattooed and ready for release from the machine shop.
After 26 years with the Schering-Plough Corporation, Dr. Spiegel retired in 2009 as chief medical officer and senior vice president of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. He initially joined Schering-Plough as director of clinical research for oncology and rose to hold various positions including senior director of clinical research for oncology and anti-infectives, vice president of clinical research and senior vice president of worldwide clinical research. Prior to Schering-Plough, Dr, Spiegel held academic positions at the National Cancer Institute and New York University Cancer Center. Following a residency in internal medicine, he completed a fellowship in medical oncology at the National Cancer Institute. He currently is an adjunct assistant professor at New York University Medical Center. Dr. Spiegel holds an M.D. from the University of Pennsylvania and a B.A. from Yale University.
Susan M. Molineaux
Dr. Molineaux has more than 20 years of biotechnology industry experience. She currently serves as Chief Executive Officer and President of Calithera Biosciences, Inc., which she co-founded in June 2010. Prior to Calithera, Dr. Molineaux co-founded Proteolix, Inc. where she served as Chief Scientific Officer from December 2003 until December 2005 and from February 2009 until November 2009, and as President and Chief Executive Officer from January 2006 until February 2009. Dr. Molineaux was responsible for leading the development of Proteolix's second generation proteasome inhibitor, carfilzomib (now marketed as Kryprolis), for the treatment of multiple myeloma, from discovery through completion of clinical trials for accelerated approval, until the company's acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc. She served as Vice President of Biology at Praelux, Inc. from 1999 to 2000, and from 1994 through 1999, as Vice President of Drug Development at Praecis Pharmaceuticals, Inc. From 1989 until 1994, she was a scientist in the Immunology group at Merck & Co. Dr. Molineaux holds a B.S. degree in Biology from Smith College and a Ph.D. degree in Molecular Biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University. She currently serves as the Co-Vice Chair of Bay Bio, Northern California's Life Science Association, and as a member of the board of directors of We Teach Science, a San Francisco Bay Area mentoring program for students in math and science.